Terms: = Cervical cancer AND KMT2D, ENSG00000167548, 8085, MLL2 AND Treatment
14 results:
1. Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic cervical cancer: Genomic Profiling Relating to Clinical Efficacy.
Zhang Q; Zhang J; Liu Z; Wang J; Wang F; Wang T; Shi F; Su J; Zhao Y
Drug Des Devel Ther; 2023; 17():3507-3522. PubMed ID: 38046281
[TBL] [Abstract] [Full Text] [Related]
2. Assessing the Genomic Landscape of cervical cancers: Clinical Opportunities and Therapeutic Targets.
Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
[TBL] [Abstract] [Full Text] [Related]
3. Sodium Valproate Modulates the Methylation Status of Lysine Residues 4, 9 and 27 in Histone H3 of HeLa Cells.
Rocha MA; de Campos Vidal B; Mello MLS
Curr Mol Pharmacol; 2023; 16(2):197-210. PubMed ID: 35297358
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic cervical cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
Xu Q; Wang J; Sun Y; Lin Y; Liu J; Zhuo Y; Huang Z; Huang S; Chen Y; Chen L; Ke M; Li L; Li Z; Pan J; Song Y; Liu R; Chen C
J Clin Oncol; 2022 Jun; 40(16):1795-1805. PubMed ID: 35192397
[TBL] [Abstract] [Full Text] [Related]
5. Can we reduce dose to ureters as avoidance organs for MRI based brachytherapy for cervical cancer? A dosimetric feasibility study.
Koerner SA; Baig T; Kim H; Rodríguez-López J; Keller A; Beriwal S
Brachytherapy; 2022; 21(2):202-207. PubMed ID: 34980569
[TBL] [Abstract] [Full Text] [Related]
6. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.
Lee SY; Chae DK; Lee SH; Lim Y; An J; Chae CH; Kim BC; Bhak J; Bolser D; Cho DH
BMC Cancer; 2020 Jul; 20(1):694. PubMed ID: 32718341
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S; Popovic M; de la Rochefordiere A; Girard E; Dureau S; Mandic A; Koprivsek K; Samet N; Craina M; Margan M; Samuels S; Zijlmans H; Kenter G; Hillemanns P; Dema S; Dema A; Malenkovic G; Djuran B; Floquet A; Garbay D; Guyon F; Colombo PE; Fabbro M; Kerr C; Ngo C; Lecuru F; Campo ERD; Coutant C; Marchal F; Mesgouez-Nebout N; Fourchotte V; Feron JG; Morice P; Deutsch E; Wimberger P; Classe JM; Gleeson N; von der Leyen H; Minsat M; Dubot C; Gestraud P; Kereszt A; Nagy I; Balint B; Berns E; Jordanova E; Saint-Jorre N; Savignoni A; Servant N; Hupe P; de Koning L; Fumoleau P; Rouzier R; Kamal M
EBioMedicine; 2019 May; 43():253-260. PubMed ID: 30952619
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in kmt2d mutants.
Kalu NN; Mazumdar T; Peng S; Tong P; Shen L; Wang J; Banerjee U; Myers JN; Pickering CR; Brunell D; Stephan CC; Johnson FM
Cancer Lett; 2018 Sep; 431():64-72. PubMed ID: 29807113
[TBL] [Abstract] [Full Text] [Related]
9. Emerging role of mutations in epigenetic regulators including mll2 derived from The cancer Genome Atlas for cervical cancer.
Li X
BMC Cancer; 2017 Apr; 17(1):252. PubMed ID: 28390392
[TBL] [Abstract] [Full Text] [Related]
10. Dosimetric analysis of 3D image-guided HDR brachytherapy planning for the treatment of cervical cancer: is point A-based dose prescription still valid in image-guided brachytherapy?
Kim H; Beriwal S; Houser C; Huq MS
Med Dosim; 2011; 36(2):166-70. PubMed ID: 20488690
[TBL] [Abstract] [Full Text] [Related]
11. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer.
Pötter R; Dimopoulos J; Georg P; Lang S; Waldhäusl C; Wachter-Gerstner N; Weitmann H; Reinthaller A; Knocke TH; Wachter S; Kirisits C
Radiother Oncol; 2007 May; 83(2):148-55. PubMed ID: 17531904
[TBL] [Abstract] [Full Text] [Related]
12. Low-dose-rate vs. high-dose-rate intracavitary brachytherapy for carcinoma of the cervix: The University of Alabama at Birmingham (UAB) experience.
Falkenberg E; Kim RY; Meleth S; De Los Santos J; Spencer S
Brachytherapy; 2006; 5(1):49-55. PubMed ID: 16563997
[TBL] [Abstract] [Full Text] [Related]
13. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix.
Nag S; Erickson B; Thomadsen B; Orton C; Demanes JD; Petereit D
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):201-11. PubMed ID: 10924990
[TBL] [Abstract] [Full Text] [Related]
14. Signal characteristics of tumors shown by high-resolution endorectal coil magnetic resonance imaging may predict outcome among patients with cervical carcinoma treated with irradiation. A preliminary study.
Corn BW; Schnall MD; Milestone B; King S; Hauck W; Solin LJ
Cancer; 1996 Dec; 78(12):2535-42. PubMed ID: 8952562
[TBL] [Abstract] [Full Text] [Related]
